Alzheimer's disease clinical trial intelligence

Home-based Transcranial Direct Current Stimulation (tDCS) for Pain Management in Persons With Alzheimer's Disease and Related Dementias

Home-based Transcranial Direct Current Stimulation (tDCS) for Pain Management in Persons With Alzheimer's Disease and Related Dementias is a NA clinical asset sponsored by Florida State University in Alzheimer's Disease and Related Dementias. SEO and diligence focus: Active tDCS, Sham tDCS, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Alzheimer's Disease and Related Dementias

Demonstration of ALIGN: Aligning Medications With What Matters Most

Demonstration of ALIGN: Aligning Medications With What Matters Most is a NA clinical asset sponsored by Johns Hopkins University in Polypharmacy, Alzheimer's Disease and Related Dementias, Mild Cognitive Impairment. SEO and diligence focus: Pharmacist-led deprescribing intervention, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Alzheimer's Disease and Related Dementias

Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases

Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases is a NA clinical asset sponsored by Kuopio University Hospital in Alzheimer Disease, Frontotemporal Dementia, Dementia With Lewy Bodies. SEO and diligence focus: Gamma tACS (40 Hz) over the superior parietal cortex, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Alzheimer Disease

An Open-label, Non-randomized Study to Evaluate the Efficacy and Safety of BAY94-9172 (ZK 6013443) Positron Emission Tomography (PET) Imaging for Detection/Exclusion of Cerebral Beta-amyloid When Compared to Postmortem Histopathology

An Open-label, Non-randomized Study to Evaluate the Efficacy and Safety of BAY94-9172 (ZK 6013443) Positron Emission Tomography (PET) Imaging for Detection/Exclusion of Cerebral Beta-amyloid When Compared to Postmortem Histopathology is a PHASE3 clinical asset sponsored by Lantheus Biosciences Ltd. in Alzheimer Disease. SEO and diligence focus: Florbetaben (BAY94-9172), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Alzheimer Disease

A Phase 1 Study Consisting of a Double-Blind, Placebo Controlled Multiple Dose Study of TRx0037 in Healthy Elderly Volunteers

A Phase 1 Study Consisting of a Double-Blind, Placebo Controlled Multiple Dose Study of TRx0037 in Healthy Elderly Volunteers is a PHASE1 clinical asset sponsored by TauRx Therapeutics Ltd in Alzheimer's Disease. SEO and diligence focus: TRx0037, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Alzheimer's Disease

A Double-Blind, Randomized, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of V950 Formulated on Aluminum-Containing Adjuvant With or Without ISCOMATRIX™ in Patients With Alzheimer Disease

A Double-Blind, Randomized, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of V950 Formulated on Aluminum-Containing Adjuvant With or Without ISCOMATRIX™ in Patients With Alzheimer Disease is a PHASE1 clinical asset sponsored by Merck Sharp & Dohme LLC in Alzheimer Disease. SEO and diligence focus: V950, ISCOMATRIX™, Placebo to V950, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Alzheimer Disease

A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease

A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease is a PHASE1 clinical asset sponsored by NKGen Biotech, Inc. in Moderate Alzheimer Disease. SEO and diligence focus: SNK01, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Moderate Alzheimer Disease

Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Bumetanide in Patients With Alzheimer's Disease.

Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Bumetanide in Patients With Alzheimer's Disease. is a PHASE2 clinical asset sponsored by Stanford University in Alzheimer Disease. SEO and diligence focus: Bumetanide, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Alzheimer Disease

Evaluation of [18F]MC225-PET to Measure P-glycoprotein Function in Neurodegenerative Disease

Evaluation of [18F]MC225-PET to Measure P-glycoprotein Function in Neurodegenerative Disease is a PHASE1 clinical asset sponsored by University Medical Center Groningen in Neurodegenerative Diseases, Alzheimer Disease, Parkinson Disease, Mild Cognitive Impairment. SEO and diligence focus: [18F]MC225, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Alzheimer Disease

A Proof-of-Concept, Multicentre, Phase IIb, Randomized Double-Blind Crossover Trial of Levetiracetam vs Placebo for Hippocampal Hyperactivity in Cognitively Normal Individuals at Risk for Alzheimer's Disease

A Proof-of-Concept, Multicentre, Phase IIb, Randomized Double-Blind Crossover Trial of Levetiracetam vs Placebo for Hippocampal Hyperactivity in Cognitively Normal Individuals at Risk for Alzheimer's Disease is a PHASE2 clinical asset sponsored by Sunnybrook Health Sciences Centre in Hippocampal Hyperactivation, Prodromal Alzheimer Disease. SEO and diligence focus: Levetiracetam (LEV), Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Prodromal Alzheimer Disease

Clinical Trial to Evaluate the Efficacy and Security of Deep Brain Stimulation in Alzheimer´s Disease

Clinical Trial to Evaluate the Efficacy and Security of Deep Brain Stimulation in Alzheimer´s Disease is a NA clinical asset sponsored by Hospital San Carlos, Madrid in Alzheimer Disease. SEO and diligence focus: Deep brain stimulation (fornix), Deep brain stimulation (Basal nucleus of Meynert), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Alzheimer Disease

A Study of the Effect of Concomitant Administration of BMS-708163 on the Pharmacokinetics of Donepezil in Healthy Subjects

A Study of the Effect of Concomitant Administration of BMS-708163 on the Pharmacokinetics of Donepezil in Healthy Subjects is a PHASE1 clinical asset sponsored by Bristol-Myers Squibb in Alzheimer Disease. SEO and diligence focus: Donepezil, BMS-708163, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Alzheimer Disease

Cause or Effect: Untangling the Relationship With Amyloid and Tau Deposits to Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study

Cause or Effect: Untangling the Relationship With Amyloid and Tau Deposits to Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study is a PHASE2 clinical asset sponsored by Neil M Rofsky, MD, MHA in Alzheimer Disease, Cognitive Decline. SEO and diligence focus: [18F]AV-1451, Positron Emission Tomography, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Alzheimer Disease

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Pharmacokinetics of MK-1942 Administered to Alzheimer's Disease Patients Receiving Donepezil Treatment.

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Pharmacokinetics of MK-1942 Administered to Alzheimer's Disease Patients Receiving Donepezil Treatment. is a PHASE1 clinical asset sponsored by Merck Sharp & Dohme LLC in Alzheimer's Disease. SEO and diligence focus: MK-1942, Donepezil, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Alzheimer's Disease

Compensatory Training to Support Everyday Function and Adherence to Brain Healthy Lifestyle Changes in Those at Risk for Alzheimer's Disease

Compensatory Training to Support Everyday Function and Adherence to Brain Healthy Lifestyle Changes in Those at Risk for Alzheimer's Disease is a NA clinical asset sponsored by Mayo Clinic in Cognitive Symptom, Pre Senile Dementia, Alzheimer Disease. SEO and diligence focus: Cognitive rehabilitation and health behavior change intervention, Self-implementation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Alzheimer Disease

Internet-based Insomnia Intervention to Prevent Cognitive Decline in Older Adults With Mild Cognitive Impairment (SHUTi MIND)

Internet-based Insomnia Intervention to Prevent Cognitive Decline in Older Adults With Mild Cognitive Impairment (SHUTi MIND) is a PHASE2 clinical asset sponsored by University of Virginia in Insomnia, Cognitive Dysfunction, Mild Cognitive Impairment, Sleep Initiation and Maintenance Disorders, Sleep Disorders, Intrinsic, Dyssomnias, Sleep Wake Disorders, Nervous System Diseases, Alzheimer Disease. SEO and diligence focus: SHUTi OASIS, Patient Education, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Alzheimer Disease

NYSCF Scientific Discovery Biobank

NYSCF Scientific Discovery Biobank is a registry-stage clinical asset sponsored by New York Stem Cell Foundation Research Institute in ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder. SEO and diligence focus: Biological Sample Collection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Alzheimer Disease

Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for AD: "Statins in Healthy, At-Risk Adults: Impact on Amyloid and Regional Perfusion (SHARP)" Study

The SHARP study investigates the potential of simvastatin, a widely used cholesterol-lowering medication, to reduce beta-amyloid levels and improve cerebral perfusion in adults at risk for Alzheimer's disease (AD). Given the increasing prevalence of AD and the lack of effective preventive therapies, successful outcomes could position simvastatin as a novel preventive treatment in the AD market. The study's findings may enhance the commercial viability of simvastatin beyond its current indications, potentially attracting interest from pharmaceutical companies focused on neurodegenerative diseases. Competitive implications include the need to monitor other AD-modifying therapies in development, particularly those targeting amyloid pathology. Diligence should focus on the regulatory landscape and potential market access challenges for repurposed drugs.

Matched by conditions: Alzheimer's Disease

A Phase 2A Multicentre, Randomised, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Study of PQ912 in Subjects With Early Alzheimer's Disease

Vivoryon Therapeutics N.V. is advancing PQ912, a glutaminyl cyclase inhibitor, in the treatment of early Alzheimer's disease, specifically targeting Mild Cognitive Impairment (MCI) and mild dementia due to Alzheimer's Disease (AD). The global Alzheimer's disease therapeutics market is projected to grow significantly, driven by increasing prevalence and demand for effective treatments. PQ912's unique mechanism of action positions it competitively against existing therapies, particularly in a landscape where disease-modifying treatments are scarce. The completion of this Phase 2A trial provides critical data that may enhance investor confidence and attract potential partnerships or acquisition interest, especially if preliminary efficacy results are favorable.

Matched by conditions: Alzheimer's Disease

A Single-Centre, Double-Blind, Randomised, Parallel Group Study of Repeated Oral Doses of AZD3480/Placebo and a Single Dose of Aripiprazole to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Aripiprazole in Healthy Subjects (Phase I)

The study evaluates the pharmacokinetic interaction between AZD3480, an investigational compound by AstraZeneca, and Aripiprazole, an established antipsychotic. Given the increasing focus on drug-drug interactions, particularly in the context of polypharmacy in Alzheimer's disease patients, the findings could inform dosing strategies and safety profiles for concurrent use. The results may enhance AstraZeneca's portfolio in neurodegenerative diseases, potentially positioning AZD3480 as a complementary treatment option alongside existing therapies. Market implications include addressing the unmet need for effective Alzheimer's treatments and navigating competitive landscapes with other neuropharmaceuticals. Diligence considerations should include the safety profile and regulatory pathways for AZD3480, especially in light of its interaction with widely used medications like Aripiprazole.

Group-Based Telehealth Music Therapy Intervention for Patients With Dementia: A Pilot Study

The pilot study sponsored by Geisinger Clinic explores the feasibility of a telehealth music therapy intervention for patients with mild to moderate dementia. Given the increasing prevalence of dementia and the associated caregiver burden, this intervention addresses a significant unmet need in supportive care. The market for dementia care solutions is expanding, with a growing focus on non-pharmacological interventions. If successful, this study could position Geisinger Clinic as a leader in innovative dementia care, potentially attracting partnerships or funding for larger-scale trials. Competitive implications include the need to monitor similar telehealth and music therapy initiatives, as well as traditional dementia care solutions that may be impacted by positive outcomes from this study.

Matched by conditions: Alzheimer Disease

LifeZig System for Individuals With Alzheimer's Disease

The LifeZig system, developed by Photozig, Inc., targets the Alzheimer's disease and dementia market, which is experiencing significant growth due to the aging population. The intervention aims to improve the quality of life for patients and reduce caregiver burden, positioning it as a supportive care solution. The competitive landscape includes traditional reminiscence therapies and other cognitive engagement tools. Given the increasing prevalence of dementia, this asset could capture a substantial market share if proven effective. Diligence should focus on reimbursement pathways, potential partnerships with healthcare providers, and scalability of the technology.

Matched by conditions: Alzheimer's Disease

A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease

Cognition Therapeutics is advancing CT1812, a novel oral treatment targeting synaptic density in patients with mild to moderate Alzheimer's disease. The Alzheimer's disease market is projected to grow significantly, driven by increasing prevalence and demand for effective therapies. With a focus on synaptic health, CT1812 may differentiate itself from existing treatments by addressing cognitive decline through a unique mechanism. Competitive analysis indicates a crowded landscape with several anti-amyloid and tau-targeting therapies; however, CT1812's distinct approach may provide a strategic advantage. Diligence considerations should include the safety profile, regulatory pathway, and potential for partnerships or licensing agreements, particularly given the involvement of the National Institute on Aging (NIA) as a collaborator.

Matched by conditions: Alzheimer Disease

Use of 7T Multimodal Imaging to Detect Brain Changes Associated With Light Therapy in Persons With Mild Cognitive Impairment and Mild Alzheimer's Disease

The study sponsored by the Icahn School of Medicine at Mount Sinai aims to explore the effects of light therapy on sleep, memory, and brain function in patients with Mild Cognitive Impairment (MCI) and Mild Alzheimer's Disease (AD). Given the prevalence of sleep disturbances in these populations, which can affect overall health and cognitive function, successful outcomes could lead to the development of innovative light-delivery methods that address these issues. The potential market for cognitive enhancement therapies in aging populations is significant, particularly as the global prevalence of Alzheimer's disease continues to rise. The findings may position the sponsor favorably within the growing field of non-pharmacological interventions for cognitive disorders, although competition from existing and emerging therapies will need to be monitored closely.

Matched by conditions: Alzheimer's Disease

Volunteers Adding Life in Dementia (VALID)

The VALID trial, sponsored by Queen's University, focuses on a volunteer-led program aimed at addressing neuropsychiatric symptoms in dementia patients, specifically those with Alzheimer's disease. Given the increasing prevalence of dementia and the limited efficacy of pharmacological treatments, this program could represent a significant advancement in non-pharmacological care strategies. The outcomes may enhance patient quality of life and reduce caregiver and staff stress, potentially positioning the VALID program as a scalable model for long-term care facilities. The market for dementia care solutions is expanding, and successful results could lead to partnerships with healthcare providers and potential funding opportunities. Competitive implications include the need to monitor similar initiatives in the non-pharmacological space, particularly those that leverage volunteer engagement.

Matched by conditions: Alzheimer Disease

A Double-Blind, Placebo-Controlled, Double-Dummy Study of Donanemab and RG6289 in PSEN1 E280A Mutation Carriers, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Donanemab, RG6289, or the Combination of Donanemab and RG6289, in the Treatment of Autosomal-Dominant Alzheimer's Disease

This clinical trial, sponsored by Banner Health, investigates the efficacy and safety of donanemab and RG6289 in treating Autosomal-Dominant Alzheimer's Disease (ADAD) in PSEN1 E280A mutation carriers. The trial's dual approach—targeting both amyloid and tau—positions it strategically in the competitive landscape of Alzheimer's therapeutics, where combination therapies are gaining traction. The estimated enrollment of 240 participants and the involvement of notable collaborators, including the National Institute on Aging, enhance the study's credibility. The trial's outcomes could significantly influence market dynamics, particularly if positive results are achieved, potentially leading to a first-in-class combination therapy for ADAD.

Practice Effects and Amyloid Imaging Using 18F-PIB (18F-39-F-6-OH-BTA1) Known as [18FGE067]) or Flutemetamol PET and FDG-PET

The clinical trial conducted by the University of Utah focuses on the early detection of Alzheimer's disease (AD) through the evaluation of amyloid plaque binding and cognitive practice effects using advanced PET imaging techniques. Given the increasing prevalence of AD and the urgent need for early diagnostic tools, this study positions itself within a growing market for biomarkers and imaging agents in neurodegenerative diseases. The competitive landscape includes other imaging agents like 18F-PIB and FDG-PET, which are already in use, but the unique focus on practice effects as an early marker may provide a differentiated approach. Diligence should consider the regulatory pathway for imaging agents, potential partnerships for commercialization, and the implications of the findings on clinical practice guidelines for AD diagnosis.

Matched by conditions: Alzheimer's Disease

Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects

LY2886721, developed by Eli Lilly and Company, is positioned within the competitive landscape of Alzheimer's Disease therapeutics, targeting a critical mechanism associated with amyloid beta production. The completion of this Phase 1 study indicates progress towards understanding the safety and pharmacokinetics of LY2886721, which may enhance Eli Lilly's portfolio in a market characterized by high unmet needs and significant competition from other amyloid-targeting therapies. The results could inform future development strategies and potential partnerships, as well as influence investor sentiment regarding Eli Lilly's pipeline in neurodegenerative diseases.

Matched by conditions: Alzheimer's Disease

A Double-Blind, Placebo-Controlled, Randomised, 4-Week Safety and Tolerability Study of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease on Pre-Existing Stable Acetylcholinesterase Inhibitor and/or Memantine Therapy

TRx0237, developed by TauRx Therapeutics, aims to address the unmet need in Alzheimer's disease treatment, particularly for patients already on acetylcholinesterase inhibitors and/or memantine. The market for Alzheimer's therapeutics is significant, with increasing prevalence and limited effective options. The termination of this study for administrative reasons raises concerns about the asset's viability and may impact investor confidence. Competitive analysis indicates that while there are several players in the Alzheimer's space, TRx0237's unique mechanism targeting tau pathology could differentiate it if safety and efficacy are established.

Matched by conditions: Alzheimer's Disease

Understanding Circadian Responses to Light in Persons With Mild Cognitive Impairment and Alzheimer's Disease

The study conducted by the Icahn School of Medicine at Mount Sinai aims to explore the effects of different light conditions on melatonin levels and memory in individuals with mild cognitive impairment and healthy controls. Given the increasing prevalence of Alzheimer's disease and related cognitive disorders, this research could lead to novel therapeutic strategies that leverage light exposure to improve cognitive function. The findings may have significant implications for the development of light-based interventions or devices targeting circadian rhythms, potentially creating a new market segment within cognitive health and wellness. Competitively, this study positions the sponsor at the forefront of innovative approaches to managing cognitive decline, although further research and validation will be necessary to establish clinical efficacy and market viability.

Matched by conditions: Alzheimer Disease

Old School Hip Hop: Parent Follow-Up & Spanish Speakers Inclusion

The 'Old School Hip Hop' program, sponsored by Columbia University, represents an innovative approach to dementia education targeting both children and their parents. The program's focus on enhancing dementia literacy and reducing stigma in diverse communities, particularly among Spanish-speaking families, positions it well within the growing market for Alzheimer's Disease awareness and education initiatives. As the prevalence of Alzheimer's continues to rise, effective educational programs that engage younger demographics may attract interest from healthcare providers, educational institutions, and non-profit organizations focused on dementia care. The inclusion of Spanish-speaking families also highlights a strategic move to address health disparities in underserved populations, potentially opening avenues for partnerships and funding opportunities. The completion of this trial may provide valuable data to support future funding applications and collaborations aimed at expanding dementia education initiatives.

Rehabilitation and Prophylaxis of Anomia in Primary Progressive Aphasia

The study, sponsored by Georgetown University, targets rehabilitation and prophylaxis of anomia in patients with Primary Progressive Aphasia (PPA) and Alzheimer's Disease. Given the increasing prevalence of dementia-related disorders, successful outcomes could position this intervention as a novel therapeutic approach in cognitive rehabilitation, potentially opening avenues for commercialization in the growing dementia care market. The focus on word-finding issues may also attract interest from pharmaceutical companies and investors looking to enhance cognitive function therapies, especially as the aging population expands. Competitive implications include the need to monitor similar interventions targeting cognitive decline, particularly those that leverage behavioral therapies or neuroplasticity.

Matched by conditions: Alzheimer Disease

Auditory Rehabilitation With Hearing Aids and Cognition in Alzheimer Patients

The trial, sponsored by University Hospital, Tours, investigates the impact of auditory rehabilitation on cognitive decline in Alzheimer's patients, a growing demographic with significant unmet needs. The market for hearing aids is expanding, particularly among the elderly population, which is increasingly affected by both hearing loss and cognitive disorders. If the trial demonstrates efficacy, it could position hearing aids as a critical component of Alzheimer's care, potentially leading to increased adoption and sales in this segment. Competitive analysis should focus on existing cognitive therapies and hearing aid manufacturers, assessing their market strategies and product offerings. Due diligence should include evaluating regulatory pathways and reimbursement scenarios in France and other European markets.

Matched by conditions: Alzheimer's Disease

Biomarkers of Nonsteroidal Anti-Inflammatories

The BONSAI study, sponsored by the National Institute on Aging, aims to explore the effects of ibuprofen on biomarkers linked to Alzheimer's Disease. Given the increasing prevalence of Alzheimer's and the growing demand for effective treatments, this study could provide critical insights into the potential repurposing of ibuprofen as a therapeutic option. If successful, the findings may open avenues for commercialization in the neurodegenerative disease market, which is projected to grow significantly. However, the competitive landscape includes numerous ongoing trials targeting similar pathways, necessitating careful monitoring of emerging data and competitor strategies.

Matched by conditions: Alzheimer's Disease

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of FK962 in Subjects With Mild to Moderate Alzheimer's Disease

The clinical trial for FK962, sponsored by Astellas Pharma Inc, was designed to evaluate its safety and efficacy in patients with mild to moderate Alzheimer's disease. The trial was terminated, which raises concerns regarding the drug's viability in a competitive market characterized by a high demand for effective Alzheimer's treatments. Given the increasing prevalence of Alzheimer's disease, any potential therapeutic that demonstrates efficacy could capture significant market share. However, the termination of this trial suggests potential challenges in achieving desired clinical outcomes or safety profiles, necessitating further diligence on Astellas' pipeline and strategic direction in the Alzheimer's space.

Matched by conditions: Alzheimer's Disease

Development of a Personalized Intervention to Motivate Health Behavior Change in Midlife Adults at Risk for Alzheimer's Disease

The clinical trial, sponsored by Rhode Island Hospital, focuses on developing a personalized intervention to motivate health behavior changes in midlife adults at risk for Alzheimer's disease. This initiative addresses a significant unmet need in the Alzheimer's prevention market, targeting a demographic that is increasingly aware of lifestyle factors influencing cognitive health. The intervention's dual approach—basic and enhanced education—positions it competitively against existing lifestyle modification programs. Given the rising prevalence of Alzheimer's disease, successful outcomes could lead to partnerships with healthcare providers and potential integration into preventive health strategies, enhancing market penetration. The trial's focus on modifiable risk factors aligns with current trends in preventive medicine, suggesting a favorable environment for commercialization if proven effective.

Matched by conditions: Alzheimer Disease

An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML007C-MA in Adult Participants With Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis

ML-007C-MA is being developed by MapLight Therapeutics as a treatment for hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP). The market for Alzheimer's-related psychosis treatments is significant, given the increasing prevalence of Alzheimer's disease globally. The competitive landscape includes existing therapies and emerging candidates targeting similar indications. Successful outcomes in this trial could position ML-007C-MA favorably within this market, particularly if it demonstrates superior safety and tolerability profiles compared to current options. Diligence implications include assessing the robustness of the antecedent study (ML-007C-MA-221) and the potential for regulatory hurdles given the patient population's vulnerability.

Matched by conditions: Psychosis Associated With Alzheimer's Disease

Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE) - A Phase II Exploratory Study

The LAPSE trial, sponsored by Walter Reed National Military Medical Center, explores the efficacy of levetiracetam in alleviating neuropsychiatric symptoms in Alzheimer's disease patients with seizure-like activity. Given the increasing recognition of seizures in Alzheimer's patients, this study could position levetiracetam as a dual-action therapy addressing both cognitive decline and neuropsychiatric symptoms. The market for Alzheimer's treatments is substantial, with a growing demand for therapies that can improve quality of life. If successful, this trial could enhance levetiracetam's marketability beyond its current use as an anti-epileptic drug, potentially leading to expanded indications and increased revenue streams. Competitive implications include the need to monitor other emerging therapies targeting neuropsychiatric symptoms in dementia.

Matched by conditions: Alzheimer Disease

Deep Brain Therapy With Low-intensity Ultrasound for Treatment of Cognitive Impairment

The trial, sponsored by the University of Utah, aims to evaluate a novel non-invasive therapeutic approach for Alzheimer's disease, a condition with significant unmet medical need and a growing market. The use of low-intensity ultrasound for cognitive impairment may position the Diadem prototype as a competitive alternative to existing pharmacological treatments, particularly if it demonstrates efficacy in improving cognitive outcomes. The Alzheimer's disease market is projected to reach $20 billion by 2025, highlighting the commercial potential of successful interventions. However, the termination of this trial due to IRB administrative closure raises concerns regarding regulatory compliance and operational viability, necessitating further diligence on the sponsor's capacity to navigate these challenges.

Matched by conditions: Alzheimer Disease

Effects of Treatment With Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid

This clinical trial, sponsored by Hamilton Health Sciences Corporation, investigates the potential disease-modifying effects of doxycycline and rifampicin on Alzheimer's disease biomarkers. Given the increasing prevalence of Alzheimer's and the limited efficacy of current treatments, successful outcomes could position these antibiotics as novel therapeutic options, potentially capturing a significant share of the Alzheimer's treatment market. The trial's completion in 2010 suggests that data may be available for analysis, which could inform future development strategies and partnerships. However, the competitive landscape includes established therapies and ongoing research into disease-modifying agents, necessitating thorough diligence to assess market entry strategies and potential collaborations.

Matched by conditions: Alzheimer's Disease

Induction of Salivary Neuromodulators by Chanting and Breathing Exercise

The study investigates the potential of ancient Tamil practices (chanting and breathing exercises) to stimulate the secretion of NGF in saliva, which has implications for neurodegenerative diseases such as Alzheimer's disease (AD). Given the increasing prevalence of AD and the limitations of current pharmacological treatments, this non-invasive approach could represent a novel therapeutic strategy. The findings may open avenues for further research and development of NGF as a therapeutic target, potentially leading to new market opportunities in neurodegenerative disease management. The integration of complementary and alternative medicine into mainstream healthcare could enhance patient outcomes and reduce healthcare costs, positioning this research favorably in the evolving biopharma landscape.

Matched by conditions: Alzheimer Disease

Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

The clinical trial for [123I] MNI-308, sponsored by Molecular NeuroImaging, aimed to evaluate its efficacy as an imaging biomarker for beta-amyloid burden in Alzheimer's disease (AD) patients compared to healthy controls. The termination of the trial due to preliminary data indicating that [123I] MNI-308 is not a useful tool for detecting AD suggests significant challenges in the market for imaging agents targeting amyloid deposition. This outcome may limit the commercial viability of [123I] MNI-308 and reflects broader competitive pressures in the neuroimaging market, particularly as other imaging modalities and biomarkers are being explored. Stakeholders should consider the implications of this termination for future investment and development strategies in neurodegenerative disease diagnostics.

Matched by conditions: Alzheimer Disease

The Brain Eye Amyloid Memory (BEAM) Study: Validation of Ocular Measures as Potential Biomarkers for Early Detection of Brain Amyloid and Neurodegeneration

The BEAM study, sponsored by Sunnybrook Health Sciences Centre, aims to validate non-invasive ocular measurements as biomarkers for early detection of neurodegenerative diseases, including Alzheimer's Disease and Mild Cognitive Impairment. This study is positioned in a growing market focused on early diagnostics for dementia, which is increasingly critical as the global aging population expands. The findings could enhance the competitive landscape for diagnostic tools in neurodegeneration, potentially leading to partnerships or licensing opportunities with companies specializing in ocular imaging and neurodegenerative diagnostics. The study's collaboration with GE Healthcare indicates a strategic alignment with industry leaders, enhancing its commercial viability.

Matched by conditions: Alzheimer's Disease

Phase 4 Study of a Reminiscence Program to Improve Quality of Life of Alzheimer's Disease Long Term Care Residents Using a Randomized Controlled Trial

The Phase 4 study conducted by Universidad Nacional de Rosario aims to validate the effectiveness of a reminiscence program in enhancing the quality of life for long-term care residents with Alzheimer's disease. Given the increasing prevalence of Alzheimer's and the growing demand for effective non-pharmacological interventions, this study could position reminiscence therapy as a viable treatment option in the dementia care market. The results may influence market dynamics by providing evidence for reimbursement and adoption in care facilities, potentially impacting competitors focused on pharmacological solutions. Stakeholders should consider the implications of these findings for future product development and partnerships in the geriatric care sector.

Matched by conditions: Alzheimer's Disease

Efficacy of Gamification in Enhancing User Engagement in Visual Mapping Assistive Technology

MapHabit, Inc. is exploring the efficacy of gamification in its assistive technology aimed at individuals with mild to moderate Alzheimer's disease and related dementias. The market for dementia care technologies is expanding, driven by an increasing aging population and a growing need for innovative solutions to improve patient engagement and caregiver support. The competitive landscape includes various digital health solutions targeting dementia care, but few incorporate gamification as a core feature. Successful outcomes from this trial could position MapHabit favorably in the market, potentially leading to partnerships or acquisition interest from larger healthcare companies. Diligence should focus on the scalability of the technology and the regulatory landscape, given that the MapHabit system is not classified as a regulated medical device.

Matched by conditions: Alzheimer Disease

A Phase 2, Randomized, Placebo Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) And Parkinson's Disease (PD) Patients

The trial, sponsored by Istanbul Medipol University Hospital, explores a novel combination of metabolic cofactors aimed at improving cognitive and motor functions in AD and PD patients. Given the increasing prevalence of these neurodegenerative diseases, successful outcomes could position this therapy favorably in a competitive market that includes established treatments and emerging therapies. The combination approach may offer a differentiated product profile, appealing to both patients and healthcare providers. Further, the collaboration with industry partners like ScandiBio Therapeutics AB suggests potential for commercialization and broader market access. Diligence should focus on the safety profile and efficacy data to assess market entry viability and reimbursement potential.

The SARTAN-AD Trial: A Randomized, Open Label, Proof of Concept Study of Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients

The SARTAN-AD trial, sponsored by Sunnybrook Health Sciences Centre, aimed to explore the potential of repurposing Telmisartan, an angiotensin receptor blocker (ARB), as a neuroprotective agent in mild to moderate Alzheimer's Disease (AD) patients. The study's termination due to recruitment challenges highlights the difficulties in enrolling participants for Alzheimer's trials, a common issue in this therapeutic area. Should the proof of concept yield positive results, it could pave the way for larger studies, potentially altering treatment paradigms for AD and expanding market opportunities for Telmisartan and Perindopril in this indication. The competitive landscape includes established AD therapies and emerging candidates, necessitating a thorough assessment of clinical efficacy and safety profiles to ensure differentiation.

Matched by conditions: Alzheimer's Disease

A Study to Examine the Effect of Therapeutic Light on Sleep, Circadian Rhythm, and Global Function in Women With Alzheimer's Disease

This study, sponsored by Yale University, investigates the effects of timed therapeutic light on sleep and circadian rhythms in women with Alzheimer's Disease (AD). Given the increasing prevalence of AD, particularly among women, there is a growing market for interventions that address sleep disturbances associated with this condition. The results may position the therapeutic light intervention as a supportive care option, potentially leading to partnerships with device manufacturers or healthcare providers focused on AD management. Competitive implications include the need to assess existing therapies targeting sleep disorders in AD, as well as the potential for intellectual property development around the specific light therapy protocols used in this study.

Matched by conditions: Alzheimer's Disease

Tailored Activity to Improve Affect in Dementia

The Tailored Activity to Improve Affect in Dementia (TAP) project, sponsored by Thomas Jefferson University, focuses on a behavioral intervention designed to enhance the quality of life for dementia patients and alleviate caregiver burden. Given the increasing prevalence of dementia, particularly Alzheimer's disease, this intervention addresses a significant unmet need in the market. The potential for scalability and integration into existing care frameworks could position this program favorably against traditional pharmacological treatments. However, competitive analysis should consider other behavioral and psychosocial interventions currently in development or practice. The results of this trial may inform future funding opportunities and partnerships, particularly in the realm of caregiver support and dementia care solutions.

Matched by conditions: Alzheimer's Disease

A Phase 1 Study to Assess the Pharmacokinetics of Different Multiple Dose Regimens of CT1812 in Older Healthy Volunteers

Cognition Therapeutics is advancing CT1812 through a Phase 1 clinical trial aimed at assessing its pharmacokinetics in older healthy volunteers. The focus on Alzheimer's disease positions CT1812 within a significant and growing market, as the global Alzheimer's therapeutics market is projected to reach $20 billion by 2025. Given the increasing prevalence of Alzheimer's and the limited efficacy of current treatments, CT1812 could represent a novel therapeutic option. However, the competitive landscape includes established players and emerging biotech firms, necessitating a robust strategy for differentiation and market entry. Diligence should focus on the safety profile and pharmacokinetic data to gauge potential for further development.

Matched by conditions: Alzheimer Disease

The Effect of Community Intervention on Different Degrees of Dementia: A Randomized Controlled Study

The clinical trial, sponsored by Babujinaya Cela at Buraidah Central Hospital, aims to evaluate the efficacy of a structured Community Intervention program on cognitive function and activities of daily living in elderly patients with Alzheimer's disease. Given the increasing prevalence of Alzheimer's and related dementias, this study addresses a significant unmet need in geriatric care. If successful, the findings could support the development of community-based therapeutic strategies, potentially leading to partnerships with healthcare providers and institutions focused on elderly care. The market for dementia care solutions is expanding, and positive results could position the sponsor favorably against competitors in the behavioral intervention space.

Matched by conditions: Alzheimer Disease

Impact of Hypno-analgesia, Non-drugs Technique of Care, on Pain That May Inverve During a Lumbar Puncture for Diagnosis of Patient With Mild to Moderate Alzheimer's Dementia.

The clinical trial, sponsored by the University Hospital of Montpellier, aimed to evaluate the efficacy of hypno-analgesia combined with EMLA patch versus standard care in reducing pain during lumbar punctures in patients with mild to moderate Alzheimer's disease. The trial was withdrawn due to internal organizational issues and dysfunction of study materials, indicating potential challenges in operational execution. The market for Alzheimer's diagnostics and associated procedures remains significant, with a growing focus on patient-centered care and non-pharmacological interventions. Companies investing in innovative pain management solutions may find opportunities in this space, particularly as the demand for improved patient experiences in invasive procedures increases.

Matched by conditions: Alzheimer Disease

Lifestyle for the BRAin Health - Nutrition and Exercise Training Intervention, LIBRA-NET

The LIBRA-NET trial, sponsored by the Slovak Academy of Sciences, is positioned within the growing market for non-pharmacological interventions aimed at addressing the rising incidence of dementia, particularly Alzheimer's disease. With an increasing focus on lifestyle modifications as adjunct therapies, this study may provide valuable insights into the efficacy of combined aerobic-strength training and nutritional counseling versus cognitive training. Should the trial demonstrate significant benefits, it could enhance the competitive landscape for lifestyle-based interventions, potentially influencing future treatment guidelines and patient management strategies. The results may also attract interest from stakeholders in the health and wellness sectors, including fitness and nutritional companies, as well as pharmaceutical firms exploring complementary approaches to cognitive health.

Matched by conditions: Alzheimer Disease

A Randomized Control Trial of an Intervention for Couples Coping With Alzheimer's Disease

The trial, sponsored by the Alzheimer's Association, aims to evaluate a couples counseling intervention designed to improve the psychosocial well-being of both partners in a relationship affected by early-stage Alzheimer's disease. Given the increasing prevalence of Alzheimer's and the significant emotional burden it places on caregivers and patients alike, this intervention could address a critical gap in supportive care. The market for Alzheimer's-related therapies is substantial, with a growing demand for non-pharmacological interventions that enhance quality of life. Competitive implications suggest that successful outcomes could position the Alzheimer's Association as a leader in psychosocial interventions, potentially attracting partnerships or funding for broader implementation. Diligence considerations should focus on the scalability of the intervention and its integration into existing care frameworks.

Matched by conditions: Alzheimer Disease

A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects.

Icure Pharmaceutical Inc. is conducting a Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of a Donepezil patch formulation in healthy male subjects. The trial's completion in December 2014 indicates that the company has likely gathered critical data on the pharmacokinetic profile of the transdermal delivery system. Given the competitive landscape of Alzheimer's disease treatments, particularly with the ongoing development of alternative delivery methods and formulations, successful outcomes could position Icure favorably in the market. However, the presence of established competitors and the need for further clinical validation may pose challenges in achieving market entry. The focus on a male-only cohort may limit broader applicability and market potential unless further studies are conducted.

Matched by conditions: Alzheimer Disease

An Observational, Multi-Center Study to Demonstrate That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease

The observational study conducted by Janssen Korea, Ltd. aimed to correlate changes in attention measures with caregiver burden in Alzheimer's patients treated with Galantamine. Given the increasing prevalence of Alzheimer's disease and the growing market for dementia therapies, this study could provide valuable insights into the efficacy of Galantamine in improving both patient outcomes and caregiver experiences. The results may strengthen Janssen's position in the Alzheimer's treatment market, particularly against competitors focusing on similar cholinergic pathways. However, the observational nature of the study limits the ability to draw definitive conclusions about causality, which may affect the commercial viability of Galantamine as a first-line treatment option.

Matched by conditions: Alzheimer's Disease

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease

MK-0677, an investigational drug developed by Merck Sharp & Dohme LLC, targets cognitive decline in Alzheimer's disease (AD), a significant market with a growing patient population. The Phase 2 trial, completed in January 2006, involved 512 participants and aimed to evaluate the drug's efficacy in slowing AD progression. Despite the potential market opportunity, the competitive landscape includes established therapies and emerging candidates, necessitating thorough diligence to assess MK-0677's unique value proposition and market entry strategy.

Matched by conditions: Alzheimer's Disease

A Single Arm Study of Resting State Functional Magnetic Resonance Imaging (Rs-fMRI)-Guided Theta Burst Stimulation (TBS) in Early-Stage Alzheimer's Disease (AD)

This pilot study sponsored by HealthPartners Institute explores a novel non-invasive treatment for early-stage Alzheimer's disease (AD) using rs-fMRI-guided iTBS. Given the limited efficacy of existing FDA-approved AD medications, this approach may represent a significant advancement in AD management, potentially addressing a substantial unmet medical need. The Alzheimer's market is projected to grow significantly, driven by the increasing prevalence of the disease, which currently affects 6.2 million individuals in the U.S. alone. The study's completion and subsequent results could position HealthPartners Institute favorably in the competitive landscape of AD therapies, particularly if efficacy is demonstrated. However, the absence of expanded access may limit immediate commercial opportunities.

Matched by conditions: Alzheimer Disease

Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil

Idalopirdine, developed by H. Lundbeck A/S as an adjunctive therapy to donepezil for mild to moderate Alzheimer's disease, aims to address a significant unmet need in the Alzheimer's treatment market. The global Alzheimer's disease therapeutics market is projected to grow substantially, driven by increasing prevalence and a growing aging population. The competitive landscape includes established therapies like donepezil and emerging candidates targeting different mechanisms. Successful outcomes from this trial could position Idalopirdine favorably against competitors, potentially leading to market entry and revenue generation. However, the presence of existing therapies and the need for robust efficacy data will necessitate thorough diligence and market analysis.

Matched by conditions: Alzheimer's Disease

Effect of Pulsatile GnRH Therapy on Cognition in Down Syndrome: Randomized Placebo Control Study

The clinical trial, sponsored by Professor Nelly Pitteloud at the Centre Hospitalier Universitaire Vaudois, investigates the efficacy of pulsatile GnRH therapy in improving cognitive and olfactory functions in adults with Down syndrome (DS). Given the increasing life expectancy of DS individuals and the lack of existing treatments for cognitive decline and olfactory defects, this study addresses a significant unmet medical need. If successful, the therapy could capture a niche market within the broader neurodegenerative disease landscape, particularly targeting cognitive dysfunction associated with early Alzheimer's disease in DS. The potential for market entry is bolstered by the absence of direct competitors focusing on this specific indication, although broader cognitive enhancement therapies may pose indirect competition. Diligence should focus on regulatory pathways, reimbursement strategies, and the scalability of treatment delivery via subcutaneous pumps.

Matched by conditions: Alzheimer Disease, Early Onset

Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase 1

The Phase 1 trial of allopregnanolone for mild cognitive impairment (MCI) and early Alzheimer's disease (AD) aims to establish safety and tolerability, with a focus on determining the maximally tolerated dose. Given the increasing prevalence of Alzheimer's disease and the limited treatment options available, successful outcomes could position allopregnanolone as a novel therapeutic approach in a competitive market. The collaboration with the National Institute on Aging (NIA) enhances credibility and may facilitate future funding opportunities. The trial's completion in February 2018 indicates that further analysis and potential progression to later phases could attract interest from larger pharmaceutical companies looking to expand their neurology portfolios.

Matched by conditions: Alzheimer Disease

Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging

The study conducted by Loma Linda University aims to establish normative values for cerebral blood flow (CBF) across various brain regions using a novel MRI technique. This non-invasive method has potential applications in diagnosing and managing brain disorders such as traumatic brain injury, multiple sclerosis, and Alzheimer's disease. The successful establishment of normative CBF values could enhance the reliability of pCASL MRI in clinical settings, positioning it as a competitive alternative to existing imaging modalities. The market for advanced neuroimaging techniques is growing, driven by increasing incidences of neurological disorders and the demand for non-invasive diagnostic tools. Companies developing or utilizing similar imaging technologies may face competitive pressures, and the findings from this study could influence their product development strategies.

Matched by conditions: Alzheimer's Disease

Effects of the Zinde Zihin Multidomain Lifestyle Program on Alzheimer's Disease Risk: A Two-Center Controlled Intervention Study

The Zinde Zihin multidomain lifestyle program targets the growing market of cognitive health interventions for older adults, particularly in institutional settings such as nursing homes. With an increasing global aging population and rising concerns about Alzheimer's disease, this program addresses a significant unmet need for preventive strategies. The intervention's culturally adapted approach may offer a competitive advantage in Turkey and similar markets. The completion of this study could provide valuable data for potential partnerships with healthcare providers and institutions focused on geriatric care, as well as opportunities for scaling the program to other regions or populations. Further, the findings may support applications for funding or grants aimed at cognitive health initiatives.

Matched by conditions: Alzheimer Disease

Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

Eli Lilly's donanemab is currently under investigation in a Phase 3 clinical trial aimed at assessing its safety and efficacy in early symptomatic Alzheimer's disease. The global market for Alzheimer's therapeutics is substantial, with increasing demand for effective treatments as the aging population grows. The competitive landscape includes other amyloid-targeting therapies, such as aducanumab and lecanemab, which have received varying degrees of regulatory approval and market acceptance. Successful outcomes from this trial could position Eli Lilly favorably in the market, potentially leading to significant revenue generation upon approval. However, the company must navigate the complexities of reimbursement and market access, particularly given the scrutiny surrounding the efficacy of similar agents.

Matched by conditions: Alzheimer Disease

A Multiple Ascending Dose, Phase 1, Double-Blind, Study to Investigate the Safety and Pharmacokinetics of NTRX-07 in Healthy Volunteers and Patients With Early Alzheimer's Disease (AD), With an Exploratory Fed-Fasted Assessment

NeuroTherapia, Inc. is advancing NTRX-07, an investigational orally administered CB2 agonist, through a Phase 1 clinical trial targeting early Alzheimer's Disease (AD) and mild cognitive impairment (MCI). The Alzheimer's therapeutics market is projected to grow significantly, driven by the increasing prevalence of the disease and the demand for effective treatments. NTRX-07's unique mechanism of action may position it favorably against existing therapies, particularly in a landscape where disease-modifying treatments are scarce. The completion of this trial could enhance NeuroTherapia's portfolio and attract potential partnerships or acquisitions, especially if safety and pharmacokinetic profiles are favorable.

Matched by conditions: Alzheimer Disease

Using Behavioral Economics and Implementation Science to Advance the Use of Genomic Medicine Utilizing an EHR Infrastructure Across a Diverse Health System

The University of Pennsylvania's clinical trial aims to innovate the implementation of genomic medicine by utilizing behavioral economics and advanced EHR systems. This approach targets a growing market for genetic testing, particularly as indications expand and the clinical utility of genetic results becomes increasingly recognized. The trial's focus on non-geneticist clinician and patient nudges positions it uniquely within the competitive landscape, potentially leading to improved patient outcomes and increased adoption of genetic testing across diverse health systems. The findings could influence reimbursement strategies and policy-making in genomic medicine, presenting opportunities for partnerships with EHR vendors and genetic testing laboratories.

Matched by conditions: Alzheimer Disease

A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease

ABBV-8E12, an investigational therapy by AbbVie, is positioned in the competitive landscape of Alzheimer's Disease treatments, particularly targeting early stages of the disease. The market for Alzheimer's therapies is expanding, driven by increasing prevalence and demand for effective treatments. AbbVie's focus on tau pathology may provide a differentiated approach compared to existing amyloid-targeting therapies. The successful completion of this Phase 2 trial may enhance AbbVie's portfolio and attract partnerships or acquisitions, given the high unmet need in this therapeutic area.

Matched by conditions: Alzheimer's Disease

Open Label Positron Emission Tomography Study With [18F]AZD4694 and [11C]AZD2184, Candidate Radioligands for AB Amyloid, to Determine and Compare in Vivo Brain Uptake and Distribution in Healthy Volunteers and Patients With Alzheimer's Disease

The clinical trial conducted by AstraZeneca evaluates two candidate radioligands, [18F]AZD4694 and [11C]AZD2184, for their efficacy in imaging Aβ amyloid depositions in Alzheimer's Disease (AD) patients. Given the increasing prevalence of AD and the growing demand for effective diagnostic tools, successful outcomes from this study could position AstraZeneca favorably in the neuroimaging market. The trial's completion in 2009 suggests that AstraZeneca may have already progressed to subsequent phases or alternative studies, potentially enhancing their portfolio in Alzheimer's diagnostics. The competitive landscape includes other pharmaceutical companies and imaging technology firms focusing on similar radioligands, necessitating continuous monitoring of advancements in this space.

Matched by conditions: Alzheimer's Disease

Safety, Tolerability and Efficacy Study of Tricaprilin (AC-1202) Administered for Ninety Days in Subjects With Probable Alzheimer's Disease of Mild to Moderate Severity

Cerecin's tricaprilin is positioned in the Alzheimer's disease market, which is characterized by a high unmet need for effective treatments. The asset's focus on metabolic modulation presents a novel approach compared to traditional therapies. Given the increasing prevalence of Alzheimer's disease and the aging population, successful outcomes could lead to significant market opportunities. However, the competitive landscape includes established players with advanced therapies, necessitating robust clinical data to differentiate tricaprilin. Diligence should focus on potential partnerships for commercialization and the regulatory pathway, especially considering the FDA's scrutiny on Alzheimer's treatments.

Matched by conditions: Alzheimer's Disease

A Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous MABT5102A Administered in a Single-Dose, Dose-Escalation Stage Followed by a Multidose, Parallel-Treatment Stage in Patients With Mild to Moderate Alzheimer's Disease

MABT5102A, developed by Genentech, is positioned within a competitive landscape of Alzheimer's Disease therapies, particularly those targeting amyloid-beta. The Phase I trial aims to establish safety and pharmacokinetics, which are critical for advancing to later stages. Given the growing demand for effective Alzheimer's treatments, successful outcomes could enhance Genentech's portfolio and market share in a sector with significant unmet needs. The trial's completion suggests readiness for potential Phase II studies, contingent upon favorable safety and efficacy data. The competitive landscape includes other amyloid-targeting therapies, necessitating a robust differentiation strategy for MABT5102A.

Matched by conditions: Alzheimer's Disease

Development of Memesto Wearable Repetitive Message/Music Therapy Device That Senses and Reduces Agitation in Alzheimer's Disease and Alzheimer's Disease Related Dementia (AD/ADRD) Individuals

The Memesto device, developed by Edgewater Safety Systems, targets a significant unmet need in the management of agitation in AD/ADRD patients, a condition affecting approximately 70% of the 7.2 million individuals in the U.S. The device aims to reduce reliance on pharmacological interventions, thereby potentially lowering healthcare costs and improving patient quality of life. The market for dementia care solutions is growing, driven by an aging population and increasing prevalence of dementia-related disorders. Competitive analysis indicates a limited number of direct competitors in the wearable therapeutic device space for dementia, positioning Memesto favorably. The successful completion of this trial could enhance Edgewater's market position and attract potential partnerships or acquisitions from larger healthcare entities focused on innovative dementia care solutions.

Exploratory Evaluation of [11C]MPC6827 Pharmacokinetics With Positron Emission Tomography (PET)

The exploratory study of [11C]MPC6827 represents a significant step in the development of diagnostic imaging for neurodegenerative diseases such as Alzheimer's Disease and ALS. Given the increasing prevalence of these conditions, the potential market for effective diagnostic tools is substantial. The results of this study could position [11C]MPC6827 as a novel imaging agent, enhancing the ability to visualize microtubule changes associated with these diseases. Competitive implications include the need to monitor other emerging imaging agents targeting similar pathways. Diligence should focus on the regulatory pathway and potential partnerships for further development and commercialization.

Matched by conditions: Alzheimer Disease

Intergenerational Connections: Reminiscence and Digital Storytelling to Improve Social and Emotional Well-being of Older Adults With ADRD

The clinical trial, sponsored by The University of Texas at Arlington, investigates the effectiveness of a reminiscence and digital storytelling intervention aimed at enhancing the social and emotional well-being of older adults with Alzheimer's disease and related dementias (ADRD). Given the projected increase in the population of older adults with ADRD, estimated to reach 7.1 million by 2025, this intervention addresses a significant market need for non-pharmacological approaches to improve quality of life in this demographic. The study's findings could lead to scalable interventions that may be implemented across various community settings, potentially attracting interest from healthcare providers, aging services organizations, and academic institutions. The collaboration with the Retirement Research Foundation aligns with their mission to enhance the quality of life for older adults, indicating a supportive ecosystem for further development and dissemination of the intervention.

A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Eisai Co., Ltd.'s BAN2401 is positioned in the competitive landscape of Alzheimer's disease therapeutics, particularly targeting patients with mild cognitive impairment and mild Alzheimer's disease. The market for Alzheimer's treatments is substantial, driven by an aging population and increasing prevalence of the disease. However, the competitive environment includes several other amyloid-targeting therapies and disease-modifying agents. Successful outcomes from this trial could enhance Eisai's portfolio and provide a strategic advantage, particularly if BAN2401 demonstrates superior safety and efficacy compared to existing therapies. Diligence should focus on regulatory pathways, potential market access challenges, and ongoing developments from competitors in the Alzheimer's space.

Improving Affect and Behavior in Assisted Living Residents

The clinical trial, sponsored by the University of Washington, addresses a significant unmet need in the assisted living sector, where over half of residents suffer from dementia-related mood and behavioral issues. The intervention focuses on training caregivers, which could enhance care quality and resident outcomes. Given the increasing aging population and the prevalence of dementia, this program has substantial market potential. The collaboration with the National Institute of Mental Health (NIMH) indicates a strong endorsement of the study's relevance and potential impact. Companies operating in the dementia care space may face competitive pressures if the training program demonstrates efficacy, leading to potential partnerships or acquisitions in the caregiver training domain.

Matched by conditions: Alzheimer Disease

WeCareAdvisor: A Web-Based Tool to Improve Quality of Life for Military Veterans With Dementia and Their Caregivers

The WeCareAdvisor tool represents a novel approach to supporting caregivers of military veterans with dementia, addressing a significant and growing market need as the aging veteran population increases. The intervention's focus on medication-free behavioral management strategies positions it favorably within the supportive care landscape, potentially reducing healthcare costs associated with more intensive interventions. Given the increasing prevalence of dementia and the unique challenges faced by military families, this tool could capture a substantial share of the caregiver support market. Competitive analysis indicates limited direct competition for similar web-based tools specifically targeting military veterans, suggesting a unique market position. Diligence implications include assessing scalability, integration with existing healthcare systems, and potential partnerships with veteran organizations and healthcare providers.

Matched by conditions: Alzheimer Disease

Testing Whether Choline Normalizes Lipid Metabolism in APOE4 Carriers

The clinical trial investigates the effects of choline supplementation on lipid metabolism in individuals at risk for Alzheimer's Disease (AD), particularly those carrying the APOE4 allele. Given the increasing prevalence of AD and the limited treatment options available, successful outcomes from this study could position choline as a novel dietary intervention in AD management. The market for AD therapeutics is substantial, with a growing demand for preventive strategies. Competitive analysis indicates that while several pharmaceutical agents target symptomatic relief, few focus on dietary supplements aimed at modifying disease progression. This trial could open avenues for partnerships with dietary supplement manufacturers and expand the therapeutic landscape for pre-symptomatic AD.

Matched by conditions: Alzheimer Disease

Distance Savvy: Testing Tele-Savvy, a Distance Dementia Family Caregiver Education Program

The Distance Savvy trial, sponsored by Emory University, focuses on the development and testing of Tele-Savvy, a web-based educational program aimed at informal caregivers of individuals with dementia, particularly Alzheimer's disease. This initiative addresses a significant market need as the aging population increases, leading to a higher prevalence of dementia. The program's innovative use of telehealth technology positions it favorably within the growing digital health sector, which is increasingly recognized for its potential to improve patient and caregiver outcomes. Competitive implications include potential partnerships with telehealth platforms and integration into existing caregiver support services. Diligence considerations should focus on the scalability of the program, user engagement metrics, and the potential for reimbursement models in telehealth services.

Matched by conditions: Alzheimer's Disease